A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of α4β2 Agonist ABT-894 in Adults with ADHD

@article{Bain2013ARD,
  title={A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of α4β2 Agonist ABT-894 in Adults with ADHD},
  author={Earle E. Bain and Weining Z. Robieson and Yili Lu Pritchett and Tushar Garimella and Walid Michel Abi-Saab and George Apostol and James J. McGough and Mario D. Saltarelli},
  journal={Neuropsychopharmacology},
  year={2013},
  volume={38},
  pages={405-413}
}
Dysregulation of the neuronal nicotinic acetylcholine receptor (NNR) system has been implicated in attention-deficit/hyperactivity disorder (ADHD), and nicotinic agonists improve attention across preclinical species and humans. Hence, a randomized, double-blind, placebo-controlled, crossover study was designed to determine the safety and efficacy of a novel α4β2 NNR agonist (ABT-894 (3-(5,6-dichloro-pyridin-3-yl)-1(S),5 (S)-3,6-diazabicyclo[3.2.0]heptane)) in adults with ADHD. Participants (N… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
9 Citations
44 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 44 references

Efficacy and safety of the alpha ( 4 ) beta ( 2 ) neuronal nicotinic receptor agonist ABT - 894 in patients with diabetic peripheral neuropathic

  • LE Rueter, AL Rêlo, MM Gaalen, ME Ballard, AV Terry, J Buccafusco
  • PAIN
  • 2011
Highly Influential
1 Excerpt

The use of the scopolamine-induced cognitive impairment model to translate on-target activity for ABT-894 from rodents/monkeys to humans: preclinical evidences

  • LE Rueter, AL Rêlo, MM van Gaalen, ME Ballard, AV JrTerry, J Buccafusco
  • Biochem Pharmacol
  • 2011
Highly Influential
1 Excerpt

The Adult ADHD Clinical Diagnostic Scale (ACDS) V

  • L Adler, T Spencer
  • 2004
Highly Influential
1 Excerpt

Similar Papers

Loading similar papers…